Extra tryptase from the TPSAB1 gene linked to severe allergies and increased blood cell growth
TPSAB1-derived tryptases promote myeloproliferation and anaphylaxis
This work looks at how extra tryptase caused by more copies of the TPSAB1 gene might make children and adults with allergies more likely to have severe allergic reactions and changes in bone marrow cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11326194 on NIH RePORTER |
What this research studies
Researchers will focus on people who have high baseline serum tryptase and genetic increases in TPSAB1 and collect blood and bone marrow samples to study cellular changes. They will use those human samples together with laboratory cell studies and animal models to see how TPSAB1-derived tryptases influence nearby immune and bone marrow cells. The team aims to identify why TPSAB1 is over-expressed and which tryptase activities drive myeloproliferation and anaphylaxis in living systems. Results are intended to point to specific targets for new treatments to reduce severe allergic reactions and related myeloid disorders.
Who could benefit from this research
Good fit: Ideal candidates are people (often children) with a history of severe allergic reactions and elevated baseline serum tryptase or known increased TPSAB1 copy number.
Not a fit: Patients whose allergies are not linked to elevated tryptase or TPSAB1-related myeloid changes are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could lead to therapies that prevent or reduce life-threatening anaphylaxis and treat abnormal myeloid cell growth.
How similar studies have performed: Previous studies have linked TPSAB1 copy-number increases to high baseline tryptase and greater anaphylaxis risk, but translating that finding into targeted therapies is still largely untested.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Lyons, Jonathan — University of California, San Diego
- Study coordinator: Lyons, Jonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.